Synexa Insights
The Latest Insights From Our Scientists
GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions
Good Manufacturing Practice ligand binding and potency assays are essential for ensuring the quality, safety, and regulatory compliance of biopharmaceutical products.…
Validating Immunity: How ELISpot Data Shaped the AELIX-003 HIV Cure Trial
We are proud to share our laboratory’s role in a landmark clinical study published in Nature Communications, titled “Safety, immunogenicity…
From Pathways to Proof: Targeted Phosphoproteomics and PTM Analysis with LC-MS/MS
Quadrupole mass spectrometry (LC-MS/MS) has long established itself as the workhorse of bioanalysis for small molecules, valued for its high…
Establishing Biosimilarity: Regulatory and Scientific Expectations
A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences…
Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures
We’re in the midst of a paradigm shift in biomarker science. No longer academic luxuries or exploratory afterthoughts, biomarker signatures…
Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective
The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…
Building a bioanalytical workflow for a vaccine study: The key assays and considerations
The COVID-19 pandemic put vaccines under the spotlight again, and from a scientific perspective at least, innovations have abounded.…
Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach
Oligonucleotide therapeutics have revolutionised the field of medicine over the last decade due to their potential for treating a broad…
The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions
CAR T-cell therapy has transformed cancer treatment, offering new hope for patients with aggressive B cell malignancies like acute lymphoblastic…
Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials
Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…
Allogeneic CAR-T Cell Therapies: A major step forward
In a groundbreaking clinical trial, three individuals suffering from severe autoimmune diseases have entered remission following a novel CAR T…
A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology
Are antibody-drug conjugates (ADCs), principally comprised of an antibody, a cytotoxic payload and a linker, the next therapeutic modality of…
The mpox outbreak: Variants, transmission and the boost for vaccine manufacturers
Following Covid-19, the world is collectively on high alert for anything that could indicate another pandemic. What do we know…
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
